Find a Tender
Open for tender
Official procurement procedure
Scientific Consultant for Medicines Discovery Catapult
Research and development services and related consultancy services
Location not published
Published value
£75,000
Submission deadline 19 Dec 2025, 15:00 GMT
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: MEDICINES DISCOVERY CATAPULT LIMITED: "Scientific Consultant for Medicines Discovery Catapult". Published status: active. Published value: £75,000. 1 published lot. Recorded submission deadline: 19 Dec 2025, 15:00 GMT. See the official notice for participation instructions.
| Contracting Authority | MEDICINES DISCOVERY CATAPULT LIMITED | Scope & Categories | Not published | Submission Window | Closed 19 Dec 2025, 15:00 GMT |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £75,000 |
Bidder Intelligence · Authority Profile: MEDICINES DISCOVERY CATAPULT LIMITED
Market Analytics
Derived from OCDS awards & bid statistics
Published history for MEDICINES DISCOVERY CATAPULT LIMITED. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
3.3Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 25 active published awards; 3 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityMEDICINES DISCOVERY CATAPULT LIMITED | Procedure methodNot published | Procurement categoryNot published |
Statusactive | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published28 Nov 2025, 12:36 GMT | Last source update28 Nov 2025, 12:36 GMT | Recurring procurementNot published |
ClassificationResearch and development services and related consultancy services | ||
Delivery areaLocation not published | ||
OCIDocds-h6vhtk-05eb03 | ||
What is being bought
Medicines Discovery Catapult (MDC) is an independent, not-for-profit innovation centre for drug discovery and part of the Catapult Network established by Innovate UK.
MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. It supports drug discovery innovators by making world-class expertise, facilities, complex technologies, and advanced analytics accessible to enable successful medicines discovery.
MDC develops pioneering, impactful R&D collaborations across biotech, academia, technology companies, charities, and global pharma. It brings these communities together in active, focused national programmes that target high-risk areas of patient need.
This requirement originates from the Partnership Team at Medicines Discovery Catapult (MDC), which includes national programmes across neuroscience and infection, virtual R&D, and complex medicine. The team plays a central role in enabling and accelerating UK drug discovery by identifying unmet needs, supporting ecosystem coordination, and helping to navigate the scientific and translational complexities of areas such as diseases of the brain.
To fulfil its role effectively, the team must remain consistently informed about recent scientific developments, innovation opportunities, and areas of commercial promise. This enables MDC to identify and shape collaborative initiatives, support investment cases, and build strategies aligned to evolving national and global health priorities.
The current emphasis has been on neuroscience, particularly neurodegenerative diseases, mental health, and drug discovery and delivery. Previous work has included:
• A landscape mapping exercise to inform the strategy for the Dementia Goals Programme, providing a foundational view of the UK's capabilities, gaps, and opportunities;
• Exploration of emerging scientific trends and innovation gaps within mental health, supporting the work of the Psychiatry Consortium;
• Early-stage analysis on cross-cutting opportunities within complex medicine.
Building on this initial work, MDC now seeks to expand the scope and focus of the landscape activity to include:
• Deeper insights into priority areas aligned to the Partnership Team's strategic objectives;
• A clearer understanding of challenges such as blood-brain barrier (BBB) penetration and the development of novel Central Nervous System drug modalities;
• Identification of translational and commercial opportunities across neuroscience and beyond (e.g., infectious diseases).
MDC requires a consultant to:
• Provide ongoing scientific and strategic intelligence relevant to current and future areas of focus and interest such as neuroscience, infection, CNS drug delivery, etc.
• Identify translational and commercial opportunities through horizon scanning and landscape analysis in defined scientific areas.
• Support development of investment cases and programme design by synthesising internal and external data sources.
• Produce materials including presentations, written briefs, dashboards, and updates for internal and external stakeholders.
Deliverables would be specific for each project, but it is expected that they could include:
• Monthly briefings summarising relevant scientific, policy, and/or commercial developments (oral or written).
• At least one deep-dive landscape output (e.g., dashboard, short report or slide deck) per quarter, focused on agreed priority themes (e.g., BBB, emerging modalities, patient stratification).
• Ad hoc input to internal programme development and stakeholder materials (e.g., funder presentations, project design).
The supplier must have a proven track record of delivering high quality technical writing, with strong communication skills. A minimum of 5 years' experience in technical or scientific writing, with demonstrable experience in life sciences.
Access to proprietary databases to access the relevant datasets useful for the specific projects (including OpenAlex, Europe PMC, PubMed, CrossRef, Dimensions, Lens.org (patents), ClinicalTrials.gov, WHO ICTRP, NICE Evidence). Expertise in the use of AI and language models to automate and classify data retrieval and apply thematic analyses Proven ability to synthesise scientific and commercial insights for strategic use. Previously work in areas relevant to MDC strategic mission.
What changed
From the official release history
- Published value updated to £75,000
28 Nov 2025, 12:36 GMT - Status changed to active
28 Nov 2025, 12:36 GMT - Official notice release published
28 Nov 2025, 12:36 GMT - Submission deadline changed to 19 Dec 2025, 15:00 GMT
28 Nov 2025, 12:36 GMT - Buyer information updated
28 Nov 2025, 12:36 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedactivePublished value£75,000The source published no individual title or description for this lot.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
28 Nov 2025, 12:36 GMT - Submission deadline
19 Dec 2025, 15:00 GMT
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
MEDICINES DISCOVERY CATAPULT LIMITED
Contracting authority GB-COH-09928547Documents (1)
Official links; attachments are not copied
- 28 Nov 2025, 12:36 GMT
Related procedures (0)
No related procedures published